ABBV logo

AbbVie (ABBV)

Profile

Full Name

AbbVie Inc.

Ticker Symbol

ABBV

Exchange

NYSE

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

United States

IPO

January 2, 2013

Indexes

S&P 500

Website

http://www.abbvie.com

Employees

55000

Key Details

Price

$198.47(+2.65%)

Market cap

$351.09B(Mega cap)

Last Dividend

$1.64

TTM Dividend yield

3.21%

Annual revenue

$56.33B(+3.71% YoY)

Annual EPS

$2.39(-12.13% YoY)

PE ratio

84.46

Next earnings date

Jul 25, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$198.47
ABBV price is $198.47

30-Day Relative Volume

0.69
ABBV 30-day relative volume is 0.69

Price Performance

Price Most recent change

+2.65%
ABBV price was up +2.65% on May 2, 2025

Price YTD change

+11.69%
ABBV price is up +11.69% since January 1st

Price 1-year change

+23.42%
ABBV price is up +23.42% year-on-year

Price 3-year change

+34.22%
ABBV price is up +34.22% over the past 3 years

Price Range

Price All-time high

$218.66
ABBV price is currently -9.23% below its historical high of $218.66

Price 3-year low

$130.96
ABBV price is currently +51.55% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$351.09B
ABBV market capitalization is $351.09 billion

Market cap 3-year change

+34.36%
ABBV market capitalization is up +34.36% over the past 3 years

Market cap All-time high

$383.27B
ABBV market capitalization is currently -8.40% below its historical high of $383.27 billion

Market cap sector rank

99.76%
ABBV market capitalization is higher than 99.76% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.18%
ABBV shares outstanding is up +0.18% year-on-year

Shares Outstanding 3-Year Change

+0.11%
ABBV shares outstanding is up +0.11% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.35
ABBV beta is 0.35

200-day SMA

$188.90
ABBV price is currently +5.07% above its 200-day simple moving average

50-day SMA

$197.86
ABBV price is currently +0.31% above its 50-day simple moving average

RSI

60.41
ABBV 14-day relative strength index is 60.41

Volume

0.69
ABBV 30-day relative volume is 0.69

ATR

$6.70
ABBV average true range is $6.70

10-day Historical Volatility

26.47%
ABBV 10-day historical volatility is 26.47%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$1.64
ABBV last dividend was $1.64 per share, with an ex-dividend date of April 15, 2025

Next Dividend

-
ABBV next dividend has not yet been announced

Dividend per share

Dividend per share

$6.20
ABBV annual dividend per share is $6.20

Dividend per share Sector Rank

94.25%
ABBV annual dividend per share is higher than 94.25% of companies in Healthcare sector

Dividend per share 1-Year Change

+4.73%
ABBV annual dividend per share is up +4.73% year-on-year

Dividend per share 3-Year Change

+19.23%
ABBV annual dividend per share is up +19.23% over the past 3 years

Dividend yield

Dividend yield

3.12%
ABBV annual dividend yield is 3.12%

Dividend yield Sector Rank

63.95%
ABBV annual dividend yield is higher than 63.95% of companies in Healthcare sector

Other

Payout ratio

257.71%
ABBV annual payout ratio is 257.71%

Dividends paid

$11.03B
ABBV annual dividends paid is $11.03 billion

Free cash flow

$17.83B
ABBV annual free cash flow is $17.83 billion

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$56.33B
ABBV annual revenue is $56.33 billion

Revenue Analysts estimate

$59.91B
ABBV annual revenue is currently -5.98% lower than the consensus analysts' forecast

Revenue 1-year change

+3.71%
ABBV annual revenue is up +3.71% year-on-year

Revenue Sector rank

98.43%
ABBV annual revenue is higher than 98.43% of companies in Healthcare sector

EPS

EPS

$2.39
ABBV annual earnings per share is $2.39

EPS Analysts estimate

$12.23
ABBV annual earnings per share is currently -80.45% lower than the consensus analysts' forecast

EPS 1-year change

-12.13%
ABBV annual earnings per share is down -12.13% year-on-year

EPS Sector rank

93.06%
ABBV annual earnings per share is higher than 93.06% of companies in Healthcare sector

Profit

Gross profit

$39.43B
ABBV annual gross profit is $39.43 billion

Gross margin

69.99%
ABBV annual gross profit margin is 69.99%

Operating profit

$9.14B
ABBV annual operating income is $9.14 billion

Operating margin

16.22%
ABBV annual operating profit margin is 16.22%

Net income

$4.28B
ABBV annual net profit is $4.28 billion

Net margin

7.59%
ABBV annual net profit margin is 7.59%

Expenses

Total expenses

$47.20B
ABBV annual total expenses is $47.20 billion

Operating expenses

$30.29B
ABBV annual total operating expenses is $30.29 billion

Cost of goods sold

$16.90B
ABBV annual cost of goods sold is $16.90 billion

Selling, general & administrative expenses

$14.75B
ABBV annual SGA is $14.75 billion

Depreciation and amortization

$8.39B
ABBV annual depreciation & amortization is $8.39 billion

Interest expense

$2.81B
ABBV annual interest expense is $2.81 billion

Income tax

-$570.00M
ABBV annual income tax is -$570.00 million

EBIT & EBITDA

EBIT

$9.14B
ABBV annual earnings before interest & taxes is $9.14 billion

EBITDA

$9.14B
ABBV annual EBITDA is $9.14 billion

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$135.16B
ABBV annual total assets is $135.16 billion

Non current assets

$109.58B
ABBV annual long term assets is $109.58 billion

Current assets

$25.58B
ABBV annual total current assets is $25.58 billion

Cash and cash equivalents

$5.52B
ABBV annual cash & cash equivalents is $5.52 billion

Accounts receivable

$10.92B
ABBV annual accounts receivable is $10.92 billion

Inventory

$4.18B
ABBV annual inventory is $4.18 billion

Liabilities

Total liabilities

$131.80B
ABBV annual total liabilities is $131.80 billion

Long term liabilities

$93.05B
ABBV annual total long term liabilities is $93.05 billion

Current liabilities

$38.75B
ABBV annual total current liabilities is $38.75 billion

Accounts payable

$2.94B
ABBV annual accounts payable is $2.94 billion

Debt

Total debt

$67.14B
ABBV annual total debt is $67.14 billion

Total debt 1-year change

+13.07%
ABBV annual total debt is up +13.07% year-on-year

Long term debt

$60.34B
ABBV annual long term debt is $60.34 billion

Short term debt

$6.80B
ABBV annual short term debt is $6.80 billion

Equity & Capital

Shareholders equity

$3.33B
ABBV annual stockholders equity is $3.33 billion

Book value

$3.33B
ABBV annual book value is $3.33 billion

Retained earnings

-$7.90B
ABBV annual retained earnings is -$7.90 billion

Working capital

-$13.17B
ABBV annual working capital is -$13.17 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$18.81B
ABBV annual cash flow from operations is $18.81 billion

Cash from operations 1-year change

-17.66%
ABBV annual cash flow from operations is down -17.66% year-on-year

Cash from investing

-$20.82B
ABBV annual cash flow from investing activities is -$20.82 billion

Cash from investing 1-year change

-936.34%
ABBV annual cash flow from investing activities is down -936.34% year-on-year

Cash from financing

-$5.21B
ABBV annual cash flow from financing activities is -$5.21 billion

Cash from financing 1-year change

+69.74%
ABBV annual cash flow from financing activities is up +69.74% year-on-year

CAPEX

CAPEX

$974.00M
ABBV annual capital expenditures is $974.00 million

CAPEX 1-year change

+25.35%
ABBV annual capital expenditures is up +25.35% year-on-year

Free Cash Flow

Free cash flow

$17.83B
ABBV annual free cash flow is $17.83 billion

Free cash flow 1-year change

-19.17%
ABBV annual free cash flow is down -19.17% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

69.99%
ABBV annual gross profit margin is 69.99%

Operating margin

16.22%
ABBV annual operating profit margin is 16.22%

Net margin

7.59%
ABBV annual net profit margin is 7.59%

ROA & ROE

ROA

3.17%
ABBV annual return on assets is 3.17%

ROE

62.18%
ABBV annual return on equity is 62.18%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

84.46
ABBV price to earnings ratio is 84.46

PE ratio Sector rank

87.32%
ABBV price to earnings ratio is higher than 87.32% of companies in Healthcare sector

PB Ratio

PB ratio

-
ABBV price to book ratio value is unknown

PB ratio Sector rank

-
ABBV price to book ratio is unknown

PS Ratio

PS ratio

6.12
ABBV price to sales ratio is 6.12

PS ratio Sector rank

68.13%
ABBV price to sales ratio is higher than 68.13% of companies in Healthcare sector

Enterprise value

Enterprise value

-
ABBV enterprise value value is unknown

Enterprise value Sector rank

-
ABBV enterprise value is unknown

EV/EBITDA

EV/EBITDA

-
ABBV EV/EBITDA value is unknown

EV/EBITDA Sector rank

-
ABBV EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.66
ABBV annual current ratio is 0.66

Quick ratio

0.55
ABBV annual quick ratio is 0.55

Leverage

Debt to equity

20.19
ABBV annual debt to equity ratio is 20.19

Interest coverage ratio

3.25
ABBV annual interest coverage ratio is 3.25

Risk & Stability

Piotroski F-Score

-
ABBV piotroski f-score value is unknown

Altman Z-Score

2.04
ABBV altman z-score is 2.04

Analyst ratings

Recent major analysts updates

Apr 29, 25 Guggenheim
Buy
Apr 28, 25 Morgan Stanley
Overweight
Apr 28, 25 Evercore ISI Group
Outperform
Apr 22, 25 Cantor Fitzgerald
Overweight
Apr 17, 25 Guggenheim
Buy
Apr 9, 25 Morgan Stanley
Overweight
Mar 5, 25 Wells Fargo
Overweight
Mar 4, 25 B of A Securities
Neutral
Feb 3, 25 Wells Fargo
Overweight
Feb 3, 25 UBS
Neutral

Institutional Ownership

Similar stocks

UNH logo
UnitedHealth Group Incorporated (UNH)
JNJ logo
Johnson & Johnson (JNJ)
NVO logo
Novo Nordisk A/S (NVO)
ABT logo
Abbott Laboratories (ABT)
NVS logo
Novartis AG (NVS)
AZN logo
AstraZeneca (AZN)
MRK logo
Merck & Co (MRK)
ISRG logo
Intuitive Surgical (ISRG)
TMO logo
Thermo Fisher Scientific (TMO)
  • What is the ticker symbol for AbbVie?
  • Does AbbVie pay dividends?
  • What sector is AbbVie in?
  • What industry is AbbVie in?
  • What country is AbbVie based in?
  • When did AbbVie go public?
  • Is AbbVie in the S&P 500?
  • Is AbbVie in the NASDAQ 100?
  • Is AbbVie in the Dow Jones?
  • When was AbbVie's last earnings report?
  • When does AbbVie report earnings?
  • Should I buy AbbVie stock now?

What is the ticker symbol for AbbVie?

The ticker symbol for AbbVie is NYSE:ABBV

Does AbbVie pay dividends?

Yes, AbbVie pays dividends. The last payment was $1.64, with an ex-dividend date on April 15, 2025

What sector is AbbVie in?

AbbVie is in the Healthcare sector

What industry is AbbVie in?

AbbVie is in the Drug Manufacturers - General industry

What country is AbbVie based in?

AbbVie is headquartered in United States

When did AbbVie go public?

AbbVie's initial public offering (IPO) was on January 2, 2013

Is AbbVie in the S&P 500?

Yes, AbbVie is included in the S&P 500 index

Is AbbVie in the NASDAQ 100?

No, AbbVie is not included in the NASDAQ 100 index

Is AbbVie in the Dow Jones?

No, AbbVie is not included in the Dow Jones index

When was AbbVie's last earnings report?

AbbVie's most recent earnings report was on Apr 25, 2025

When does AbbVie report earnings?

The next expected earnings date for AbbVie is Jul 25, 2025

Should I buy AbbVie stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page